Hyphens Pharma International Ltd (SGX: 1J5) is a pharmaceutical company which focuses on the sales and marketing of specialty pharmaceutical products in key ASEAN countries through exclusive distributorship or licensing agreements with brand principals mainly from Europe and United States.
The company was listed on 18th May 2018 about two years ago on the SGX Catalyst.
Since then, they have grown over the years and have done reasonably well in the midst of the pandemic outbreak through the product offerings they provide.
I was invited to their recent results briefing which I attended and had a chance to speak and ask my questions directly with their CFO, Lee Wei and CEO, See Wah.
There were also other private investors that attended the call.
Core Businesses
Before we go into that and also run through their recent Q1 FY2020 results, let me give a brief context of their main core businesses.
...